Vaccines against epidemic and pandemic influenza

Hoelscher, Mary; Gangappa, Shivaprakash; Zhong, Weimin; Jayashankar, Lakshmi; Sambhara, Suryaprakash

doi:10.1517/17425247.5.10.1139

Cited by 28 publications

(28 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ultimate goal of vaccination, of course, is to protect against the development of severe disease upon exposure to (17). It is of interest to note that the use of a higher vaccine dose (15 g of HA) did not result in the induction of higher antibody titers or increased protection against infection.…”

Section: Discussionmentioning

confidence: 99%

“…Clinical trials evaluating candidate inactivated influenza A/H5N1 virus vaccines showed that the use of adjuvants can increase their immunogenicity and broaden the specificity of the induced antibody responses (2,7,19,23,27,36,41). These research efforts have resulted in the licensing of adjuvanted vaccines against seasonal and pandemic influenza viruses (17). The protective efficacy of immune responses induced with candidate influenza A/H5N1 virus vaccines was demonstrated in ferrets after two immunizations (1,22,24,25) or after a single immunization.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets

Bodewes

Kreijtz

Amerongen

et al. 2010

J Virol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets

Bodewes

Kreijtz

Amerongen

et al. 2010

J Virol

View full text Add to dashboard Cite

“…Currently, inactivated virus and live-attenuated virus vaccines are predominantly used and administered by intramuscular injection using a hypodermic needle and nasal spray using a special syringe, respectively (2). The conventional seasonal influenza vaccines are trivalent, including two influenza A subtypes (H1N1 and H3N2) and one variant of influenza B virus (3).…”

Section: Introductionmentioning

confidence: 99%

“…Various novel vaccines have been developed such as recombinant vaccines, DNA vaccines, vaccines developed by reverse genetics, and subunit vaccines such as virus-like particles (VLP) (2,6,7). VLPs are attractive because they can expedite vaccine production and also offer the potential for improved immunogenicity and safety due to their cellbased production methods that avoid the delays and safety concerns of conventional egg-based influenza vaccine production (8).…”

Section: Introductionmentioning

confidence: 99%

Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine

et al. 2010

View full text Add to dashboard Cite

Abstract. Mortality due to seasonal and pandemic influenza could be reduced by increasing the speed of influenza vaccine production and distribution. We propose that vaccination can be expedited by (1) immunizing with influenza virus-like particle (VLP) vaccines, which are simpler and faster to manufacture than conventional egg-based inactivated virus vaccines, and (2) administering vaccines using microneedle patches, which should simplify vaccine distribution due to their small package size and possible self-administration. In this study, we coated microneedle patches with influenza VLP vaccine, which was released into skin by dissolution within minutes. Optimizing the coating formulation required balancing factors affecting the coating dose and vaccine antigen stability. Vaccine stability, as measured by an in vitro hemagglutination assay, was increased by formulation with increased concentration of trehalose or other stabilizing carbohydrate compounds and decreased concentration of carboxymethylcellulose (CMC) or other viscosity-enhancing compounds. Coating dose was increased by formulation with increased VLP concentration, increased CMC concentration, and decreased trehalose concentration, as well as increased number of dip coating cycles. Finally, vaccination of mice using microneedles stabilized by trehalose generated strong antibody responses and provided full protection against high-dose lethal challenge infection. In summary, this study provides detailed analysis to guide formulation of microneedle patches coated with influenza VLP vaccine and demonstrates effective vaccination in vivo using this system.

show abstract

“…Although vaccination programs form the backbone of public health intervention strategies, lengthy egg-derived H1N1 vaccine production timelines, suboptimal growth of vaccine strain viruses, and limited current manufacturing capacities delayed the availability of pandemic influenza vaccine (5,6). Antiviral drugs are another public health tool for prophylactic and therapeutic interventions against influenza (7,8). There are currently two classes of antiinfluenza virus drugs: the M2 ion channel blockers (amantadine, rimantadine) and the neuraminidase inhibitors (oseltamivir, zanamavir) (9).…”

mentioning

confidence: 99%

Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication

Chakravarthy

Bonoiu

Davis

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

101

View full text Add to dashboard Cite

The emergence of the pandemic 2009 H1N1 influenza virus has become a world-wide health concern. As drug resistance appears, a new generation of therapeutic strategies will be required. Here, we introduce a nanotechnology approach for the therapy of pan-demic and seasonal influenza virus infections. This approach uses gold nanorods (GNRs) to deliver an innate immune activator, pro-ducing a localized therapeutic response. We demonstrated the utility of a biocompatible gold nanorod, GNR-5′PPP-ssRNA nanoplex, as an antiviral strategy against type A influenza virus. In human respiratory bronchial epithelial cells, this nanoplex activated the retinoic acid-inducible gene I (RIG-I) pathogen recognition pathway, resulting in increased expression of IFN-β and other IFN-stimulated genes (ISGs) (e.g., PKR, MDA5, IRF1, IRF7, and MX1 ). This increase in type I IFN and ISGs resulted in a decrease in the replication of H1N1 influenza viruses. These findings suggest that further evaluation of biocompatible nanoplexes as unique antivirals for treatment of seasonal and pandemic influenza viruses is warranted.

show abstract

Vaccines against epidemic and pandemic influenza

Cited by 28 publications

References 137 publications

A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets

A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets

Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine

Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication

Contact Info

Product

Resources

About